Report From RSNA: Interest Expands In Breast Imaging Market

Several new modalities are poised to change the way breast cancer screenings and diagnostics are performed as physicians and patients continue to search for technologies that can do more than standard X-rays. Ultrasound, computed tomography, and 3-D imaging are being touted as ways to improve the detection of tumors – especially in women with dense breast tissue – as well as to reduce exposure to radiation. Currently, the market is dominated by large, established manufacturers, but some new players are bringing in innovative options that are poised to push the field forward.

The use of X-rays in medical imaging has long presented physicians with a difficult balancing act, especially when it comes to the detection and treatment of breast cancer. The technology has proven effective in helping to identify a certain portion of breast tumors; however, X-ray mammography falls short when it comes to finding breast cancer in women with dense breast tissue, and some safety concerns have begun to emerge over excessive exposure to radiation, mirroring that trend in other areas of the diagnostic imaging industry. The limitations of X-rays in detecting breast tumors, particularly those in women with dense breasts, has led to a continual cry for better technology that can not only do more, but do more while also presenting less potential for harm. The demands are high, but a large push from advocacy groups supporting women’s health issues has forced radiologists and device manufacturers to search for better solutions, and some of the results of that search are starting to hit the market.

One advance that promises to improve breast imaging is tomosynthesis, commonly referred to as three-dimensional (3-D) mammography. The difference between...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

US FDA Webinar Highlights 506J Expectations Amid Ongoing Supply Chain Vulnerabilities

 
• By 

A recent CDRH Learn module urges medical device manufacturers to report potential shortages early, even outside emergencies, to help prevent disruptions. Recent natural disasters underscore the need for resilient supply chains, and reported shortages may be added to an FDA list.

Siemens Healthineers Mitigates Headwinds With ‘Value-Add Structural Changes’

 

Siemens Healthineers anticipates €400m-€500m tariff impact by 2026 but says it will mitigate losses through structural changes and pricing. Despite a revenue decline in diagnostics due to China’s VBP, diagnostics transformation activities, including cutting product, were “successful."

Inspection Readiness 101: Be Prepared To Avoid Common Pitfalls When The FDA Comes Knocking

 

A panel of regulatory pros offered stakeholders tips for avoiding FDA citations after facility inspections. The July 29 webinar, hosted by ProPharma and Hyman Phelps and McNamara, follows the agency’s May announcement that it plans to up random foreign inspections.

Bipartisan Senate Bill Would Give Patients ‘True Price Tag’ Prior To Care

 

Pending legislation seeks to address what the sponsors argue is a lack of transparency in medical billing. If enacted, the bill would provide patients with the costs of procedures and medications before receiving them. A data collection expert discusses what the bill could mean for patients.

More from North America

Device User Fees Up About 7% For FY2026

 
• By 

The US FDA has announced its user fees for fiscal 2026, which are based on a figure of $455,000 for a PMA.

NIH-Backed Scanner Opens New Frontier For Understanding The Human Brain

 

A new MRI scanner developed by a team of scientists working with the National Institutes of Health marks a milestone in understanding the complexities of the human brain. Andrea Beckel-Mitchener with the NIH Brain Initiative discusses the significance of this potentially game-changing device.

EU/US Trade Deal Raises Questions For Medtech

 

There is still no clarity on how life sciences will be treated in the final agreement.